Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast Cancer
Featuring perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics: Long-Term Management of HER2-Positive Breast Cancer Introduction (0:00) Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27) Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24) Management of trastuzumab deruxtecan–related adverse events (7:41) Patient selection for and practical implementation of postadjuvant neratinib (13:23) Faculty presentation: Dr Krop (16:26) Optimizing the Management of ER-Positive Localized Breast Cancer Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adjuvant hormonal therapy to attempt pregnancy (24:56) Selection of patients for adjuvant tamoxifen monotherapy (29:05) Utility of genomic assays in the neoadjuvant setting; management of node-positive disease in postmenopausal patients with low-risk Recurrence Scores® (33:35) Selection between abemaciclib and ribociclib in the adjuvant setting (36:45) Potential utility of circulating tumor DNA assessment in breast cancer (41:58) Faculty presentation: Dr Kalinsky (46:36) Considerations in the Care of Patients with ER-Positive Metastatic Breast Cancer Preference of CDK4/6 inhibitor in the metastatic setting (56:42) Sequencing of trastuzumab deruxtecan in ER-positive, HER2-low metastatic breast cancer (59:00) Faculty presentation: Dr Jhaveri (1:06:39) Novel and Emerging Strategies for ER-Positive Metastatic Breast Cancer Selection of therapy for ER-positive metastatic breast cancer progressing on a CDK4/6 inhibitor; future role of capivasertib (1:19:31) Faculty presentation: Dr Rugo (1:30:39) Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC) Management of localized TNBC; selection of patients for adjuvant Olaparib (1:46:10) PARP inhibitor tolerability (1:51:55) Faculty presentation: Dr O’Shaughnessy (1:55:31) Recent Advances in the Treatment of Metastatic TNBC (mTNBC) Selection of therapy for triple-negative metastatic breast cancer; sequencing of trastuzumab deruxtecan in ER-negative, HER2-low disease (2:11:08) Faculty presentation: Prof Schmid (2:18:03) CME information and select publications